bims-myxlip 2026-06-28 papers

Issue of 2026–06–28
two papers selected by
Laura Mannarino, Humanitas Research

Cancers (Basel). 2026 Jun 12. pii: 1921. [Epub ahead of print]18(12):

Pooled Analysis of Trabectedin Efficacy in Myxoid/Round Cell Liposarcoma from Three Prospective Clinical Trials.

Michael Jason Nathenson, Lucy Hoch, Beth Ireland, Rose O'Nians Michalowicz, Dennis Williams, Neeta Somaiah.

BACKGROUND/OBJECTIVES: Trabectedin is a standard-of-care chemotherapy for recurrent/metastatic liposarcomas, including myxoid/round cell liposarcoma (MRCLS). This pooled analysis was performed to evaluate trabectedin efficacy in MRCLS across multiple trials to establish a standard-of-care efficacy baseline.
METHODS: The Yale University Open Data Access (YODA) Project was queried for prospective trabectedin trials. Data on patients with unresectable, locally advanced/metastatic MRCLS who received ≥ 1 trabectedin dose(s) (1.0-1.5 mg/m2 administered as a 24-h continuous infusion every 3 weeks) were extracted from three trials: NCT00060944, NCT00210665, and NCT01343277. The primary outcome was the objective response rate as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary outcomes included disease control rate and overall survival, defined as the time from first trabectedin administration to death. Responses were assessed using RECIST by investigators in NCT01343277 and by independent review in NCT00060944. In NCT00210665, tumor assessment followed institutional standards, so only overall survival was analyzed.
RESULTS: Sixty-three patients were included (42 from NCT01343277, 13 from NCT00060944, 8 from NCT00210665): 32% were female, the median age was 50 years, and 79% were White. The objective response rate was 16.3% (8/49) of patients (37 from NCT01343277, 12 from NCT00060944). The disease control rate was 77.6% (38/49). Overall survival data were available for 63 patients: the median overall survival was 22.51 months (95% CI: 16.99-34.33).
CONCLUSIONS: This analysis represents one of the largest pooled populations to date of patients with advanced MRCLS treated with trabectedin in prospective clinical trials to be reported. Whilst limited by typical factors affecting pooled analyses, including cross-study heterogeneity, nevertheless the results estimate a trabectedin efficacy baseline against which to inform other therapies for MRCLS.

Keywords: myxoid liposarcoma; myxoid/round cell liposarcoma; pooled analysis; sarcoma; soft tissue sarcoma; trabectedin

DOI: https://doi.org/10.3390/cancers18121921

Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2026 Jun 15. 40(6): 958-963

[Impact of unplanned surgery on prognosis of myxoid liposarcoma and analysis of salvage treatment strategies].

Guoxin Qu, Jingyu Hou, Qilong Su, Chunlei Zhang, Jiaqiang Wang, Xin Wang, Peng Zhang, Xiaohui Niu, Weitao Yao.

Objective: To compare the effectiveness of different treatment strategies after unplanned surgery for myxoid liposarcoma (MLS) and explore the clinical value of salvage therapy versus planned treatment following unplanned resection.
Methods: The clinical data of 37 MLS patients admitted between June 2014 and June 2024 who met the selection criteria were retrospectively analyzed. Patients were divided into three groups based on initial treatment status: the unplanned treatment group (group A, 14 cases, transferred after benign tumor excision without further treatment at external hospitals, presenting with local recurrence), the salvage planned treatment group (group B, 10 cases, transferred within 1 month after benign tumor excision at external hospitals), and the planned treatment group (group C, 13 cases, transferred without prior treatment or only after biopsy). No significant difference ( P>0.05) was observed among the three groups in baseline characteristics including age, height, weight, and maximum preoperative tumor diameter. Tumor recurrence or metastasis time were recorded. Overall survival (OS) and disease-free survival (DFS) rates were calculated using the Kaplan-Meier method with intergroup comparisons.
Results: All 37 patients were followed up 19-193 months (mean, 67.4 months). Group A exhibited higher tumor recurrence (28.6%) and metastasis rates (35.7%) than group B (10.0%, 10.0%) and group C (0, 23.1%), with significant differences in recurrence rates ( P<0.05), no significant differences existed between groups B and C ( P>0.05); metastasis rates showed no intergroup significance ( P>0.05). Group A demonstrated lower 1-/3-/5-year DFS (71.4%, 42.9%, 21.4%) than group B (100%, 88.9%, 74.1%) and group C (92.3%, 83.9%, 71.9%), with significant differences ( P<0.017), no significant difference existed between groups B and C ( P>0.017); 3-/5-year OS showed no intergroup significance ( P>0.05).
Conclusion: Patients with MLS should undergo standard extended resection and individualized adjuvant radiotherapy and chemotherapy as soon as possible after unplanned surgery to significantly reduce the local recurrence rate. In view of the high risk of extrapulmonary metastasis, a comprehensive preoperative assessment of metastasis is required.

Keywords: Myxoid liposarcoma; extended resection; soft tissue sarcoma; unplanned surgery

DOI: https://doi.org/10.7507/1002-1892.202512109